RxDoctor Payments Data

Lindsay Kissane, MD

Urogynecology and Reconstructive Pelvic Surgery · Orlando, FLNPI 1659633972

Payments from drug & device makers

What this record shows

10 manufacturers reported payments, led by Intuitive Surgical at 54.0% of the total. Reporting peaked in 2024 at $4,595 and has fallen 92.9% since, to $328 in 2025.

$7,771in general payments, 2019–2025

Across 87 payments — averaging $89.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$4K
  • Medtronic$2K
  • Axonics, Inc.$866
  • Boston Scientific$423
  • Coloplast$381
  • AbbVie$110
  • plus $160 from 4 others
$473in research payments, 2019–2025

Across 1 payment — averaging $472.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$473

What the payments were for

  • Food & beverage$3,77149%
  • Education$4,00051%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,771 in reported general payments places this provider in the 60th percentile of 81 urogynecology and reconstructive pelvic surgery providers in Florida.

See all urogynecology and reconstructive pelvic surgery providers in Florida

Medicare billing

Part B allowed, 2024
$207,306
Medicare patients
245
Services billed
3,078

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron126$93,311
GemtesaVibegron84$53,914
Estradiol240$14,200
Mirabegron ErMirabegron14$5,477
Tolterodine Tartrate ErTolterodine Tartrate21$1,981
Methenamine Hippurate26$1,774
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst111$1,669
Trospium Chloride28$1,532
Clobetasol Propionate17$405
Oxybutynin Chloride ErOxybutynin Chloride18$361
Tamsulosin Hcl14$329
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen69$323
Amitriptyline Hcl17$312
Ibuprofen85$290
Ciprofloxacin Hcl27$126

Paid to pharmacies, not to this prescriber.

Other urogynecology and reconstructive pelvic surgery in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →